Evidence map›Paper›PMID 37155993›Full record

Observational studyThe oncologist2023

Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer.

Guido Giordano, Raffaele Ivan Cincione, Francesca Losavio, Tiziano Senia, Arianna Aquilini Mummolo, Mario Pacilli, Vincenzo Lizzi, Giuseppina Bruno, Annamaria Piscazzi, Vincenza Conteduca and 1 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Effect of travel distance on utilization of ancillary services among patients with pancreatic ductal adenocarcinoma: A single institution study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  5. Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Guido GiordanoUnit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences - Policlinico Riuniti, University of Foggia, Foggia, Italy.ORCID 0000-0002-9310-1075
Raffaele Ivan CincioneUniversity Service of Diet Therapy and Metabolic Diseases, Department of Clinical and Exprerimental Medicine - Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Francesca LosavioUniversity Service of Diet Therapy and Metabolic Diseases, Department of Clinical and Exprerimental Medicine - Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Tiziano SeniaUniversity Service of Diet Therapy and Metabolic Diseases, Department of Clinical and Exprerimental Medicine - Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Arianna Aquilini MummoloUniversity Service of Diet Therapy and Metabolic Diseases, Department of Clinical and Exprerimental Medicine - Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Mario PacilliGeneral Surgey Unit, Department of Medical and Surgical Sciences - Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Vincenzo LizziGeneral Surgery Unit - Policlinico Riuniti, 71122 Foggia, Italy.
Giuseppina BrunoUnit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences - Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Annamaria PiscazziUnit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences - Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Vincenza ConteducaUnit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences - Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Matteo LandriscinaUnit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences - Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
University of Foggia · ITOspedali Riuniti di Foggia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAt diagnosis, more than 80% of patients with pancreatic cancer (PC) suffer from significant weight loss due to malnutrition which is a major concern for patient management, and this may negatively impact treatment outcomes and patient prognosis. PATIENTS AND

methodsWe performed an observational, retrospective study on patients with metastatic PC (mPC) undergoing first-line chemotherapy with nab-Paclitaxel containing schedules and receiving or not receiving nutritional support (NS) and pancreatic enzyme replacement therapy (PERT) to investigate their relevance in this setting.

resultsWe observed that PERT and ancillary dietary interventions are related to longer overall survival (OS; median: 16.5 vs. 7.5 months, P < .001) and have a significant, independent, prognostic impact for better outcomes (P = .013), independently from the therapeutic regimen. Furthermore, PERT and NS prevented weight loss during chemotherapy and obtained an improvement of nutritional parameters such as phase angle and free-fat mass index, after 3 months of anticancer treatment. Consistently, the positive impact on OS correlated also with the prevention of Karnofsky performance status deterioration and a lower incidence of maldigestion-related symptoms.

conclusionsOur data suggest that an early and well-conducted NS in patients with mPC may impact on survival and preserve performance status, thus improving quality of life.

Indexed as

GemcitabinePancreatic NeoplasmsAlbuminsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineHumansNutritional SupportPaclitaxelQuality of LifeRetrospective StudiesWeight LossAlbuminsDeoxycytidineGemcitabinePaclitaxelfirst-line therapymetastatic pancreatic cancernab-paclitaxelnutritional supportPERT

Identifiers

PMID37155993
PMCPMC10485404
OpenAlexW4375954898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.